Immunome, Inc. (IMNM)
| Market Cap | 778.47M |
| Revenue (ttm) | 10.13M |
| Net Income (ttm) | -305.35M |
| Shares Out | 81.77M |
| EPS (ttm) | -5.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 674,064 |
| Open | 10.24 |
| Previous Close | 10.11 |
| Day's Range | 9.51 - 10.47 |
| 52-Week Range | 8.97 - 30.96 |
| Beta | 1.90 |
| Analysts | Strong Buy |
| Price Target | 28.60 (+200.42%) |
| Earnings Date | Mar 27, 2025 |
About IMNM
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price forecast is $28.6, which is an increase of 200.42% from the latest price.
News
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Announces Pricing of Upsized Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Immunome Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced i...
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome'...
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update.
Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising p...
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the ...
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced fina...
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on re...
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $...
Immunome Appoints Phil Tsai as Chief Technical Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
Immunome Announces Completion of Purchase of Assets from Atreca
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion...
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion ...
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome to Present at 2024 Bank of America Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
Immunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
Immunome Appoints Sandra M. Swain to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...